Surrogate marker evaluation: a tutorial using R
From MaRDI portal
Cites work
- A Bayesian approach to surrogacy assessment using principal stratification in clinical trials
- A general framework to assess complex heterogeneity in the strength of a surrogate marker
- A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker
- An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference
- Assessing heterogeneity in surrogacy using censored data
- Assessing the value of a censored surrogate outcome
- Asymptotics for the SIMEX Estimator in Nonlinear Measurement Error Models
- Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpoints
- Comparing biomarkers as principal surrogate endpoints
- Criteria for Surrogate End Points
- Estimation of the proportion of treatment effect explained by a high-dimensional surrogate
- Evaluating Candidate Principal Surrogate Endpoints
- Evaluating multiple surrogate markers with censored data
- Evaluating surrogate marker information using censored data
- Evaluating Surrogate Markers of Clinical Outcome When Measured with Error
- Evaluation of longitudinal surrogate markers
- Group sequential testing of a treatment effect using a surrogate marker
- scientific article; zbMATH DE number 4044951 (Why is no real title available?)
- Identifiability and estimation of causal mediation effects with missing data
- Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm
- Links between causal effects and causal association for surrogacy evaluation in a Gaussian setting
- Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling
- Methods for mediation analysis with missing data
- Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker
- Novel criteria to exclude the surrogate paradox and their optimalities
- On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm
- On meta-analytic assessment of surrogate outcomes
- Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints
- Principal stratification in causal inference
- Quantifying the feasibility of shortening clinical trial duration using surrogate markers
- Related Causal Frameworks for Surrogate Outcomes
- Relaxed Lasso
- Robust Approach to Combining Multiple Markers to Improve Surrogacy
- Robust estimation of the proportion of treatment effect explained by surrogate marker information
- Robust methods to correct for measurement error when evaluating a surrogate marker
- Semiparametric Inference for Surrogate Endpoints with Bivariate Censored Data
- Simulation-Extrapolation Estimation in Parametric Measurement Error Models
- Solutions for Surrogacy Validation with Longitudinal Outcomes for a Gene Therapy
- Super Learner
- Surrogacy validation for time-to-event outcomes with illness-death frailty models
- Surrogate Marker Evaluation from an Information Theory Perspective
- Surrogate measures and consistent surrogates
- Testing for Heterogeneity in the Utility of a Surrogate Marker
- The Evaluation of Multiple Surrogate Endpoints
- The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
- The validation of surrogate endpoints in meta-analyses of randomized experiments
- Using a surrogate marker for early testing of a treatment effect
- Using a surrogate with heterogeneous utility to test for a treatment effect
- Weak and strong uniform consistency of kernel regression estimates
This page was built for publication: Surrogate marker evaluation: a tutorial using R
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6907468)
